Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03280667
Title Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group

renal cell carcinoma


Denosumab + Pembrolizumab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.